10-Q 1 pazoo10q093017.htm PAZOO 10Q, 09.30.17


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_____________
 
FORM 10-Q
_____________
 
 
☒   QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended: September 30, 2017

OR 
 
☐   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from _____________ to ______________ 
 
Commission File No. 333-178037
 
 PAZOO, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
 
27-3984713
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
 
 
 
34 DeForest Ave, Unit 9
East Hanover NJ
 
07936
(Address of Principal Executive Offices)
 
(Zip Code)

(973) 884-0136
(Registrant's Telephone Number, Including Area Code)
 
 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
  Yes ☒   No ☐
 
Indicate by check mark whether the registrant has submitted electronically and posted on its Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§230.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ☒   No ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated file," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. 
 
 
Large accelerated filer
☐
Accelerated filer
☐
 
Non-accelerated filer
☐  (Do not check if a smaller reporting company)
Smaller reporting company
☒
 
Emerging growth company
☐
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 
Yes ☐   No ☒
869,645,259 shares of common stock, par value $0.001 per share, outstanding as of February 7, 2018. 

 


 
Pazoo, Inc.
Form 10-Q
 
Table of Contents
 
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
 
 
 

  
 
 
 

 
PART I – FINANCIAL INFORMATION 
 
Item 1     Condensed Consolidated Financial Statements (Unaudited)

The results reflected in the unaudited Condensed Consolidated Statement of Operations for the nine month period ended September 30, 2017 may not be indicative of results expected for the full year.  The following unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Notes to the Financial Statements, Management's Discussion and Analysis of Financial Condition and Results of Operations shown in Item 2 of Part I of this report, as well as the audited financial statements and related notes to the financial statements in the Company's Annual Report on Form 10-K filed on April 21, 2017 with the Securities and Exchange Commission (SEC) for the year ended December 31, 2016.  Certain information and note disclosures normally included in annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the instructions to Article 8 Regulation S-X.
 
PAZOO, INC.
  
CONDENSED CONSOLIDATED BALANCE SHEETS
  
(Unaudited)
  
 
            
 
  
September 30,
    
December 31,
  
 
  
2017
    
2016
  
 
            
ASSETS
            
Current assets:
            
Cash
  
$
39,047
    
$
88,909
  
Prepaid expenses
    
5,536
      
5,536
  
 
                
Total current assets
    
44,583
      
94,445
  
 
                
Fixed assets, net
    
473,817
      
613,332
  
 
                
Total assets
  
$
518,400
    
$
707,777
  
 
                
LIABILITIES AND STOCKHOLDERS' DEFICIT
                
 
                
Current liabilities:
                
Lines of credit
  
$
16,070
    
$
21,039
  
Accounts payable and accrued liabilities
    
905,190
      
608,332
  
Loans payable ($1,504,449 and $546,717 to related party)
    
1,536,349
      
615,801
  
Interest payable ($416,248 and $227,033 to related party)
    
2,124,309
      
1,452,102
  
Convertible debt, net of unamortized discounts of $316,297 and $195,827
    
1,284,672
      
983,621
  
Contingent consideration liabilities
    
713,581
      
713,581
  
Derivative liabilities
    
4,304,752
      
2,925,627
  
Capital lease liabilities
    
356,712
      
373,930
  
 
                
Total current liabilities
    
11,241,635
      
7,694,033
  
 
                
Long-term liabilities:
                
Long-term portion of convertible debt, net of unamortized discounts of $0, and $110,672 ($800,000 and $800,000 to related party)
    
1,292,500
      
1,401,828
  
Capital lease liabilities
    
-
      
136,672
  
 
                
Total long-term liabilities
    
1,292,500
      
1,538,500
  
 
                
Total liabilities
    
12,534,135
      
9,232,533
  
 
                
Commitments and contingencies
                
 
                
Stockholders' deficit:
                
Convertible Preferred Stock, 50,000,000 shares authorized, $0.001 par value
  
Series A; 10,000,000 shares authorized, 215,139 and 230,401 shares issued and outstanding, respectively.
    
215
      
230
  
Series B; 5,000,000 shares authorized, 2,150,000 and 1,762,500 shares issued and outstanding, respectively.
    
2,150
      
1,762
  
Series C; 10,000,000 shares authorized, 2,643,709 and 2,621,375 shares issued and outstanding, respectively.
    
2,644
      
2,621
  
Series D; 12,500,000 shares authorized, 0 and 0 shares issued and outstanding, respectively.
    
-
      
-
  
Series E; 12,500,000 shares authorized, 0 and 0 shares issued and outstanding, respectively.
    
-
      
-
  
Common stock, $0.001 par value; 2,950,000,000 shares authorized, 123,589,339  and 9,137,630 shares issued and outstanding, respectively.
    
123,589
      
9,138
  
Additional paid-in capital
    
12,590,391
      
12,155,641
  
Accumulated deficit
    
(24,734,724
)
    
(20,694,148
)
 
                
Total stockholders' deficit
    
(12,015,735
)
    
(8,524,756
)
 
                
Total liabilities and stockholders' deficit
  
$
518,400
    
$
707,777
  
 
 
 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
 


PAZOO, INC.
  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
  
(Unaudited)
  
 
                        
 
  
Three Months Ended
    
Nine Months Ended
  
 
  
September 30,
    
September 30,
  
 
  
2017
    
2016
    
2017
    
2016
  
 
                        
Revenues:
                        
Management fees - related party
  
$
-
    
$
11,919
    
$
-
    
$
30,515
  
Advertising Sales
    
-
      
-
      
51
      
-
  
Total revenues
    
-
      
11,919
      
51
      
30,515
  
 
                                
Operating expenses:
                                
Selling, general and administrative expenses
    
188,173
      
164,144
      
1,053,777
      
2,292,314
  
Professional fees
    
81,559
      
55,278
      
428,286
      
327,162
  
Loss on impairment of license
    
-
      
-
      
-
      
1,540,207
  
Total operating expenses
    
269,732
      
219,422
      
1,482,063
      
4,159,683
  
 
                                
Loss from operations
    
(269,732
)
    
(207,503
)
    
(1,482,012
)
    
(4,129,168
)
 
                                
Other income/(expenses):
                                
Gain/(loss) on derivative liabilities
    
(2,421,000
)
    
642,948
      
(2,046,906
)
    
(3,796,031
)
Gain/(loss) on debt extinguishment
    
37,397
      
541,133
      
753,264
      
2,238,375
  
Gain on change in fair value of contingent consideration
    
-
      
-
      
-
      
5,000
  
Interest expense
    
(237,513
)
    
(1,068,853
)
    
(1,264,847
)
    
(2,735,216
)
                                 
Total other income/(expenses)
    
(2,621,116
)
    
115,228
      
(2,558,489
)
    
(4,287,872
)
 
                                
Net loss
  
$
(2,890,848
)
  
$
(92,275
)
  
$
(4,040,501
)
  
$
(8,417,040
)
 
                                
Series A preferred stock dividends
    
(16
)
    
(77
)
    
(52
)
    
(431
)
 
                                
Net loss attributable to common stockholders
  
$
(2,890,864
)
  
$
(92,352
)
  
$
(4,040,553
)
  
$
(8,417,471
)
 
                                
Basic and dilutive net loss per common share
  
$
(0.04
)
  
$
(0.04
)
  
$
(0.12
)
  
$
(8.18
)
 
                                
Weighted average common shares outstanding – basic and diluted
    
75,357,664
      
2,619,089
      
34,616,005
      
1,029,097
  

 
 
 
 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
 
 
PAZOO, INC.
 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
  
(Unaudited)
  
 
            
 
  
Nine Months Ended
  
 
  
September 30,
  
 
  
2017
    
2016
  
 
            
Cash flows from operating activities:
            
Net loss
  
$
(4,040,501
)
  
$
(8,417,040
)
Adjustments to reconcile net loss to net cash used in operating activities:
                
Amortization of debt discounts
    
480,082
      
1,246,540
  
Depreciation
    
139,515
      
71,776
  
Amortization
    
-
      
50,728
  
Change in fair value of contingent consideration
    
-
      
(5,000
)
Stock-based compensation
    
66,110
      
1,226,131
  
(Gain)/loss on derivative liabilities
    
2,046,906
      
3,796,031
  
(Gain)/loss on debt extinguishment
    
(753,264
)
    
(2,238,375
)
(Gain)/loss on impairment of intangibles
    
-
      
1,540,207
  
Changes in operating assets and liabilities:
                
Accounts receivable
    
-
      
(28,715
)
Prepaid expenses and other current assets
    
-
          
Accounts payable, accrued liabilities and interest payable
    
1,065,979
      
1,981,361
  
Net cash used in operating activities
    
(995,173
)
    
(776,356
)
 
                
Cash flows from financing activities:
                
Proceeds from convertible debt
    
523,605
      
638,460
  
Repayments on capital leases
    
(153,890
)
    
(36,685
)
Repayments on convertible debt
    
(305,757
)
    
(86,311
)
Repayments on loans payable
    
(57,100
)
    
(17,100
)
Repayment on loans payable- related party
    
(3,300
)
    
-
  
Proceeds from loans payable
    
946,722
      
170,300
  
Proceeds from sale of Series C preferred stock
    
-
      
90,000
  
Lines of credit
    
(4,969
)
    
4,049
  
Net cash provided by financing activities
    
945,311
      
762,713
  
 
                
Net decrease in cash and cash equivalents
    
(49,862
)
    
(13,643
)
 
                
Cash and cash equivalents beginning of period
    
88,909
      
16,819
  
 
                
Cash and cash equivalents end of period
  
$
39,047
    
$
3,176
  
 
                
Noncash Investing and Financing Activities
                
Common stock issued for the conversion of Series A and C preferred stock
  
$
2,634
    
$
163,659
  
Debt discount for derivative convertible feature and OID
    
471,592
      
1,353,842
  
Preferred shares issued for conversion of debt and interest
    
-
      
30,652
  
Common shares issued for conversion of debt and interest
    
483,412
      
957,808
  
Common shares issued for accrued liability
    
-
      
350,000
  
Accrued interest converted to convertible debt and loans payable
    
57,667
      
134,495
  
 
 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
 

 
Pazoo, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

 
Note 1—DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Description of Business

The Company entered the pharmaceutical testing laboratory market with their acquisitions of MA & Associates, LLC which will operate pharmaceutical testing laboratories in Nevada, and Harris Lee Holdings, LLC which will operate pharmaceutical testing laboratories within other states, or license testing protocols as independently owned laboratories.  These pharmaceutical testing laboratories focus on providing quality control services to the medical cannabis industry.  The mission is to protect the public health by providing infrastructure and analytical services to legally-authorized cannabis producers and distributors as well as to regulators.  States that have legalized cannabis are developing cannabis health and safety criteria that we will fulfill through their testing laboratories.  Harris Lee Holdings, LLC, due to Colorado residency requirements, entered into an advisory agreement with Harris Lee Colorado, LLC, a related party. Harris Lee Holdings, LLC had sub-licensed the testing protocols to Harris Lee Colorado, LLC in exchange for management fees for each test conducted.  The Colorado MED approved the transfer of management of an existing laboratory, operating as Steep Hill Colorado, to Harris Lee Colorado, LLC (a related party) and Harris Lee Holdings, LLC has derived management fees from Harris Lee Colorado, LLC in the year ending December 31, 2016.  However, because of the failure to transfer the MED license to Harris Lee Colorado, LLC, the Denver laboratory was closed by the end 2016.  The Company does not expect to re-commence operations in Colorado in the near future. Lastly, the Company's wholly owned subsidiary, CK Distribution LLC, provides the marketing and sales agent for the distribution of non-controlled hemp products throughout the USA. Non-controlled hemp products are the items utilized by the industry that support grow facilities, infusion companies and dispensaries. On January 4, 2017 the Company's 100% wholly owned subsidiary MA & Associates received its final approval and Marijuana Testing License from the City of Las Vegas, NV and can now commence operations in Las Vegas.

In the fourth quarter 2017 the Company sold a 70% Membership Interest in its wholly owned subsidiary (MA & Associates, LLC) in consideration of retirement of approximately $1,000,000 in the Company's debt and approximately $500,000 in cash (of which $117,894 was funded as of September 30, 2017). The buyer also has an option to buy an additional 10% for 18 months from the closing at a 10% premium to the 70% purchase. The Company must open the lab by February 15, 2018 or it will be considered an event of default. The Company will account for their remaining 30% interest as an equity level investment going forward.
 
Further, the business consists of pazoo.com, an online, content driven, ad supported health and wellness web site for people and their pets. Additionally, this site has e-commerce functionality which allows pazoo.com to be an online retailer of nutritional foods/supplements, wellness goods, and fitness apparel. Pazoo, Inc. does not have any brick and mortar establishments.
 
Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of Pazoo, Inc. ("Pazoo" or the "Company") and its wholly-owned subsidiaries MA & Associates, LLC, Harris Lee Holdings, LLC and CK Distributions, LLC. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). All significant inter-company transactions and accounts have been eliminated in consolidation.

In April 2017, the Company effected a 1-for-250 reverse stock split of the outstanding common stock (the "Reverse Stock Split") whereby every two hundred fifty (250) shares of outstanding common stock decreased to one (1) share of common stock. Similarly, the number of shares of common stock, par value $0.001 ("Common Stock") into which each outstanding Preferred stock is to be exercisable decreased on a 1-for-250 basis and the exercise price of each outstanding preferred stock to purchase common stock increased proportionately resulting in no effect from the reverse stock split. The impact of this reverse stock split has been retroactively applied to the consolidated financial statements and the related notes.

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the nine month period ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016 as filed on April 21, 2017.
 

Use of Estimates
 
In accordance with GAAP the preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period.
 
On an ongoing basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. The most significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. These accounting policies are described at relevant sections in the notes to the financial statements. 
 
Basic and Diluted Net Loss Per Common Share
 
Potentially Dilutive Securities
Nine Months Ended
  
 
September 30, 2017
  
September 30, 2016
  
 
        
Convertible notes
    
5,015,062,816
      
158,168,021
  
Preferred series A shares & warrants
    
21,513,900
      
92,160
  
Preferred series B
    
430,000,000
      
1,410,000
  
Preferred series C
    
264,370,900
      
1,266,829
  
 
    
5,730,947,616
      
160,937,010
  
 

The Company currently does not have sufficient authorized shares to settle the conversion of their potentially dilutive instruments, but is considering options including increasing the authorized share count. Due to the current lack of authorized shares, an additional derivative liability was recorded in the amounts of $775,000 at September 30, 2017.

Fair Value of Financial Instruments
 
The Company's condensed consolidated financial instruments consist principally of cash, derivatives, convertible debt, and accounts payable. The Company believes that the recorded values of all of its other financial instruments approximate their fair values because of their nature and respective maturity dates or durations. The fair value of long-term debt is determined by using estimated market prices. Assets and liabilities measured at fair value are categorized based on whether or not the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial instruments within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is prioritized into three levels (with Level 3 being the lowest) defined as follows:
 
Level 1: Inputs are based on quoted market prices for identical assets or liabilities in active markets at the measurement date.
Level 2: Inputs include quoted prices for similar assets or liabilities in active markets and/or quoted prices for identical or similar assets or liabilities in markets that are not active near the measurement date.
Level 3: Inputs include management's best estimate of what market participants would use in pricing the asset or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument's valuation.
 




The following table sets forth by level within the fair value hierarchy the Company's financial assets and liabilities that were accounted for at fair value as of September 30, 2017 and December 31, 2016.
 
Recurring Fair Value Measurements
Level 1
  
Level 2
  
Level 3
  
Total
  
 
                
LIABILITIES:
                
Derivative liability – September 30, 2017
  
$
-
    
$
-
    
$
4,304,752
    
$
4,304,752
  
Derivative liability – December 31, 2016
  
$
-
    
$
-
    
$
2,925,627
    
$
2,925,627
  

Recent Accounting Pronouncements
 
In February 2016, the Financial Accounting Standards Board ("FASB") issued new guidance related to how an entity should recognize lease assets and lease liabilities. The guidance specifies that an entity who is a lessee under lease agreements should recognize lease assets and lease liabilities for those leases classified as operating leases under previous FASB guidance. Accounting for leases by lessors is largely unchanged under the new guidance. The guidance is effective for us beginning in the first quarter of 2019. Early adoption is permitted.  In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The Company is evaluating the impact of adopting this guidance on our consolidated financial condition, results of operations and cash flows.
 
In January 2016, the FASB issued ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The amendments in ASU 2016-01, among other things, requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income; Requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (i.e., securities or loans and receivables); Eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities. The amendments in this ASU are effective for non-public companies for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning December 15, 2019.  Early adoption of the amendments in the ASU is permitted as early as the fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.  The adoption of this standard is not expected to have a material effect on the consolidated financial position and results of operations and statements of cash flows.
 
On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. This ASU permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. The Company does not expect the adoption of this standard to have a material effect to the financial statements.
 
In July 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity's own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. The Company is evaluating the impact of adopting this guidance.
 
 
In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718), Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The Company is evaluating the impact of adopting this guidance.

Other recent accounting pronouncements issued by the FASB did not or are not believed to have a material impact on our present or future consolidated financial statements.

Note 2—GOING CONCERN
 
During the nine months ended September 2016 and 2017, the Company incurred net losses of $8,417,040 and $4,040,501, respectively. In addition, as of September 30, 2017, the Company had a working capital deficit of $11,197,052 as well as sixteen (16) notes with past due principal balances totaling $1,504,152 and accrued default interest and associated penalties related to these instruments. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company is unable to generate sufficient cash flow or raise additional capital, it could be forced to cease operations.  The Company's continuation as a going concern is dependent upon its ability to generate sufficient cash flow and raise additional capital to meet obligations on a timely basis and ultimately attain profitability. The Company does not have sufficient capital for the next 12 months from the issuance of these financial statements. Further, the Company sold 70% of its interest in MA & Associates in the fourth quarter of 2017 which could compromise future cash flow.

The Company's liquidity is highly dependent on its ability to obtain additional capital in the near future. The Company's failure to raise new capital would impair its ability to both continue its current operations and could result in its failure to continue to operate as a going concern. Substantial doubt about its ability to continue as a going concern may also create negative reactions to the price of the Company's common stock, and the Company may not be able to obtain additional financing in the future. If the Company is unable to raise additional capital on terms acceptable to the Company and on a timely basis, the Company will be required to downsize or wind down its operations through liquidation, bankruptcy, or a sale of its assets. In addition, to the extent additional capital is raised through the sale of equity or convertible debt securities, such securities may be sold at a discount from the market price of the Company's common stock. The issuance of these securities could also result in significant dilution to some or all of the Company's stockholders, depending on the terms of the transaction. There are no assurances that the Company will be able to consummate additional capital raises.
 
Note 3—FIXED ASSETS

Fixed assets consists of the following:
 
Fixed Assets
                  
 
  
Estimated Useful Life (in years)
    
September 30,
2017
    
December 31,
2016
  
 
                  
Cost:
                  
Equipment
    
3-5
    
$
643,195
    
$
643,195
  
Furniture and fixture
    
7
      
6,687
      
6,687
  
Leasehold improvements
    
3-5
      
238,620
      
238,620
  
Website
    
3
      
1,385
      
1,385
  
 
          
$
889,887
    
$
889,887
  
 
                        
Accumulated depreciation and amortization
            
(416,070
)
    
(276,555
)
 
                        
Fixed Assets, Net
          
$
473,817
    
$
613,332
  
 
Costs of assets acquired under capital leases were approximately $615,000 as of September 30, 2017 and December 31, 2016, respectively.  The capital lease represents a total of three leases for testing equipment. The leases hold an interest rate of 0% and monthly payments are approximately $17,000 per month. The depreciation for the nine months ended September 30, 2017 and September 30, 2016 was $139,515 and $50,544, respectively. As of September 30, 2017 and December 31, 2016, accumulated depreciation related to assets under capital lease was approximately $246,009 and $211,822, respectively. All leased equipment is collateral under the respective lease agreements. As of September 30, 2017, the Company was currently in default of these lease agreements, as scheduled payments were not made. Commencing in 2017, the Company began making payments toward the capital leases again.
 

Note 4—LINES OF CREDIT

The Company entered into a line of credit with Wells Fargo in December 2015 in the amount of $25,000.  The credit line bears an interest rate of 9.75% annually, compounded daily, and there is no term on the account. There are no financial covenants and the guarantor on the account is Steve Basloe. The line of credit has been used for general operating expenses.

The Company entered into a line of credit with Wells Fargo in May 2016 in the amount of $5,000. The credit line bears an interest rate of 24.24% for the first year and then 9.75% annually, compounded daily, and there is no term on the account. There are no financial covenants and the guarantor on the account is David Cunic, the Company's former CEO and current Investor Relations Consultant. The credit has been used for general operating expenses.

The combined lines of credit at December 31, 2016 totaled $21,039 compared to $16,070 at September 30, 2017.

Note 5—DERIVATIVE LIABILITIES
 
The Company evaluates all of it financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded or freestanding derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
 
Under ASC-815 the conversion options embedded in the notes payable described in Note 6 require liability classification because they do not contain an explicit limit to the number of shares that could be issued upon settlement.
 
The following table summarizes the changes in the derivative liabilities during nine months ended September 30, 2017:
 
Balance as of December 31, 2016
  
$
2,925,627
  
 
        
Grant date fair value
    
2,030,299
  
Extinguished
    
(1,139,373
)
Change in fair value
    
488,199
  
 
        
Balance as of September 30, 2017
  
$
4,304,752
  
 
The Company uses the Black Scholes Option Pricing Model to value its convertible debt and derivative liabilities based upon the following assumptions during the nine months ended September 30, 2017 and 2016:
 
 
September 30,
2017
  
September 30,
2016
  
 
        
Dividend yield
    
0
%
    
0
%
Expected volatility
    
80
%
    
80
%
Risk-free interest rate
    
0.20% to 1.06
 %    
0.29% to 0.35
 %
Expected life (years)
    
0.00 to 0.39
      
0.01 to 1.38
  
 
During the nine months ended September 30, 2017 and 2016, the aggregate gain/(loss) on derivative liability was ($2,046,906) and ($3,796,031), respectively, consisting of initial derivative expense that equals the excess of the derivative liability over principal received and the change in fair value of the derivative liabilities.
 


 
Note 6—CONVERTIBLE NOTES
 
The following table summarizes the changes in the convertible notes in the year ended December 31, 2016 and the nine months ending September 30, 2017:
 
 
  
Short Term
    
Long Term
    
Total
  
 
                  
Balance as of January 1, 2016 - Gross
  
$
1,343,035
    
$
992,500
    
$
2,335,535
  
Cash additions
    
373,460
      
300,000
      
673,460
  
Interest added to notes payable
    
111,778
      
116,600
      
228,378
  
Cash payments
    
(118,223
)
    
-
      
(118,223
)
Conversions
    
(474,777
)
    
-
      
(474,777
)
Reassignments
    
(103,400
)
    
103,400
      
-
  
Original issue discount
    
47,575
      
-
      
47,575
  
Total
  
$
1,179,448
    
$
1,512,500
    
$
2,691,948
  
Less:  unamortized discount
    
(195,827
)
    
(110,672
)
    
(306,499
)
Balance as of December 31, 2016 - Net
  
$
983,621
    
$
1,401,828
    
$
2,385,449
  
Add back: unamortized discount
    
195,827
      
110,672
      
306,499
  
Balance as of December 31, 2016 - Gross
  
$
1,179,448
    
$
1,512,500
    
$
2,691,948
  
Cash additions
    
523,605
      
-
      
523,605
  
Interest added to notes payable
    
23,441
      
-
      
23,441
  
Cash payments
    
(305,757
)
    
-
      
(305,757
)
Conversions
    
(116,116
)
    
-
      
(116,116
)
Reclassification to short-term
    
220,000
      
(220,000
)
    
-
  
Original issue discount
    
76,348
      
-
      
76,348
  
Total gross balance
  
$
1,600,969
    
$
1,292,500
    
$
2,893,469
  
Less: unamortized discount
    
(316,297
)
    
-
      
(316,297
)
Balance as of September 30, 2017 - Net
  
$
1,284,672
    
$
1,292,500
    
$
2,577,172
  
 
 
 
Year Ended September 30,
  
 
2018
  
2019
  
2020
  
2021
  
2022
  
Thereafter
  
Total
  
                                                         
Convertible notes
  
$
1,600,969
    
$
-
    
$
-
    
$
350,000
    
$
942,500
    
$
-
    
$
2,893,469
  
Short-term non-convertible notes
    
1,536,349
      
-
      
-
      
-
      
-
      
-
      
1,536,349
  
 
  
$
3,137,318
    
$
-
    
$
-
    
$
350,000
    
$
942,500
    
$
-
    
$
4,429,818
  

In January 2017, the company entered into a convertible note agreement for an aggregate total of $206,379. The interest rate is 12% and the conversion terms are 50% of the average of the lowest 3 trading prices during the 20 trading days prior to conversion. The maturity date was December 2017. The proceeds from the note were used to pay off previous notes from the lender. The Company paid back the note as of September 30, 2017.
 
In February 2017, the Company entered into a convertible note agreement for a total of $63,800. The interest rate is 10% and the conversion terms are the lower of (a) $0.009 or (b) 45% of the lowest trading price during the 30 trading days prior to conversion. The maturity date is February 2018.

In March 2017, the Company entered into a convertible note agreement for a total of $33,000. The interest rate is 12% and the conversion terms are 65% of the average of the two lowest closing prices during the 15 trading days prior to conversion. The maturity date is December 2017.

In May 2017, the Company entered into two convertible note agreements for a total of $78,000. The interest rates range from 8% - 12% and the conversion terms are between 35% - 50% of the average of the two lowest closing prices during the 15 trading days prior to conversion. The maturity dates are February 2018.

In June 2017, the Company entered into a convertible note agreement for a total of $218,773. The interest rate is 12% and the conversion terms are 50% of the average of the two lowest closing prices during the 20 trading days prior to conversion. The maturity date is June 2018.

The Company evaluated all convertible notes describe above under ASC 815 and determined that certain conversion features qualify as derivative liabilities (see Note 5).
 

During the nine months ended September 30, 2017 the Company incurred $753,264 of a gain in debt extinguishment primarily as a result of various notes converting to equity, with the corresponding derivative liability value at the date of conversion being written off to debt extinguishment as a gain, offset by the unamortized discount on the convertible debt at the time of conversion.

In addition to the funds received, noteholders converted $116,111 during the nine months ended September 30, 2017 into common stock exclusive of accrued interest. At September 30, 2017, a total of sixteen notes with a principal balance of $1,504,152 were past due. The Company has adequately accrued all default interest and associated penalties related to these instruments. Additionally, cross default clauses exist within certain other instruments containing terms which would make the notes immediately due and payable, however no cross default clauses have been triggered as of yet.

Note 7—LOANS PAYABLE
 
 
  
Short Term
    
Long Term
    
Total
  
 
                  
Balance as of January 1, 2016
  
$
203,000
    
$
-
    
$
203,000
  
Cash additions
    
447,100
      
-
      
447,100
  
Interest added to notes payable
    
22,717
      
-
      
22,717
  
Cash payments
    
(57,016
)
    
-
      
(57,016
)
Balance as of December 31, 2016
  
$
615,801
    
$
-
    
$
615,801
  
Cash additions
    
946,722
      
-
      
946,722
  
Interest added to notes payable
    
34,226
      
-
      
34,226
  
Cash payments
    
(60,400
)
    
-
      
(60,400
)
Balance as of September 30, 2017
  
$
1,536,349
    
$
-
    
$
1,536,349
  
 
The Company received $946,722 of new cash additions in the nine months ended September 30, 2017.  Cash payments consisted of $60,400. Interest added to the note payables in the nine months ended September 30, 2017 totaled $34,226. The interest rate on the loans are 8%. In the fourth quarter 2017 the Company sold a 70% Membership Interest in its wholly owned subsidiary (MA & Associates, LLC) in consideration for retirement of approximately $1,000,000 in the Company's debt and approximately $500,000 in cash (of which $117,894 was funded as of September 30, 2017). The buyer also has an option to buy an additional 10%. The Company must open the lab by February 15, 2018 or it will be considered an event of default. The Company will account for their remaining 30% interest as an equity level investment going forward.
 
Note 8—STOCKHOLDERS' EQUITY (DEFICIT)
 
Common Stock Split

In 2017, the Company filed a Form 14-C in order to effectuate a 1-for-250 reverse stock split of the outstanding common stock (the "Reverse Stock Split") whereby every two hundred and fifty (250) shares of outstanding common stock decreases to one (1) share of common stock. The current Reverse Stock Split went effective on April 26, 2017. All shares and per share amounts have been retroactively restated for all periods presented.

Preferred Stock
 
In January 2017, the Company filed a Form 14-C Information Statement advising all shareholders of the Company that the Board of Directors, as ratified by the majority of the votes of equity holders in late April 2017, approved of a reverse stock split (at a ratio of 250:1) and setting forth the proposed terms and characteristics of the Series D Preferred Stock.  The Series D Preferred Stock will carry a 5% annual dividend, will have no voting rights prior to conversion, and will convert into common stock at a ratio which will be determined by the amount of debt to be retired, and new money to be invested, and the then outstanding common stock of the Company on a fully diluted basis.
 
The purpose of reconstituting the characteristics of the Series D Preferred Stock is to have the ability to consummate the contemplated sale of the Company's Series D Preferred Stock as set forth in the Form 14C. If, and when, the agreement has been finalized for the sale of the Series D Preferred Stock, the characteristics of the Series D Preferred Stock will be set forth in a Certificate of Designations to be filed with the Secretary of State of the State of Nevada.  If the characteristics are substantively different than as previously approved by the Board of Directors, and ratified by the majority of the votes of equity holders, new approval will be sought. The proposed terms of the agreement are to be 80% of the common stock on a fully diluted basis.
 
The conversion rates for all of the Preferred Series of Stock are not affected by the reverse stock split, effected in April 2017.
 
 
Series A
 
During 2017, 75 shares of Series A Preferred stock were issued for dividends.

In 2017, a total of 15,337 Series A Preferred stock was converted into 1,533,700 of common stock by Series A Preferred shareholders.
 
Series B
 
In 2017, the Company issued an aggregate of 387,500 Series B Preferred Stock, valued at approximately $56,000, to Board Members as compensation in connection with MA and Associates, LLC receiving its license to operate.
 
Series C
 
In 2017, a total of 11,000 Series C Preferred stock was converted into 1,100,000 of common stock by Series C Preferred shareholders.

In 2017, the Company issued an aggregate of 33,334 Series C Preferred Stock, valued at approximately $10,000, for services.
 
Series D&E
 
In 2017, there have been no issuances or sales of Series D Preferred Stock or Series E Preferred Stock as the Certificate of Designation has not been filed as it depends on the 14C Filing offering the Preferred D Series Stock.
 
Common Stock
 
During the nine months ended, September 30, 2017, the Company issued an aggregate of 111,815,524 common shares in connection with conversion of debt and interest valued at $ 483,412.
 
Note 9—RELATED PARTY TRANSACTIONS
 
In July 2013, the Company entered into a consulting agreement with an affiliate of Mr. Basloe, a board member of the Company. The agreement provides for consulting on marketing-related services for the Company. Amounts incurred under this agreement for the nine months ended September 30, 2017 and 2016, totaled $26,300 and $6,500, respectively.

In 2016, the Company managed Harris Lee Colorado, LLC, an existing lab in Denver, Colorado, after receiving approval from the Colorado Marijuana Enforcement Division in February of 2016. Harris Lee Holdings, LLC has sub-licensed the testing protocols to Harris Lee Colorado, LLC in exchange for a management fee for each test conducted. The Colorado MED has recently approved the transfer of management of an existing laboratory, to Harris Lee Colorado, LLC (a related party) and Harris Lee Holdings, LLC has begun to derive management fees from Harris Lee Colorado, LLC.  The revenue derived from these management fees for the nine months ended September 30, 2017 and 2016 are $0 and $30,515. The laboratory closed during 2016 and the Company does not have plans to re-open in the near future.
 
In August 2016, Pazoo, Inc. entered into a loan agreement with David Cunic, former Company CEO and current Investor Relations Consultant, and totaling $5,000.  The note has an interest rate of 0.70% and the maturity date is August 2018. As of September 2017, $0 remains outstanding.

In September 2016, Pazoo, Inc. entered into a loan agreement with Steve Basloe, Company President, and totaling $2,500.  The note has an interest rate of 0.70% and the maturity date is September 2018. As of September 2017, $2,500 remains outstanding.

In the fourth quarter 2017 the Company sold a 70% Membership Interest in its wholly owned subsidiary (MA & Associates, LLC) in consideration for retirement of approximately $1,000,000 in the Company's debt and approximately $500,000 in cash (of which $117,894 was funded as of September 30, 2017 and is included in the loans payable on the accompanying balance sheet). The buyer also has an option to buy an additional 10%. The Company must open the lab by February 15, 2018 or it will be considered an event of default. The Company will account for their remaining 30% interest as an equity level investment going forward.

The buyer of the 70% interest is now considered a related party.  All loans, convertible notes and accrued interest owed to the buyer, are disclosed on the face of the accompanying balance sheet, parenthetically, as related party liabilities.
 
 
Note 10—COMMITMENTS AND CONTINGENCIES

On March 10, 2015, Harris Lee signed a 9-year licensing agreement with Steep Hill Labs, LLC, with options to renew for an additional 9 years. The purpose of the agreement is to take the Steep Hill licensing to additional states to test medical marijuana above and beyond the State of Nevada, namely Oregon and Colorado. Under the license agreement for the first two states (Oregon and Colorado), if certain gross revenue thresholds are met, the Company is obligated to pay an additional $250,000. In addition, the Company is obligated to pay certain royalties over the life of the license agreement to Steep Hill Labs, Inc, based on the greater of the number of tests ($5 dollars a test) or an escalating royalty rate (7% to 15%) of the initial purchase price. The Company has the option to enter into additional states with similar commitments and royalties.  In June 2016, the Company, due to the uncertainties surrounding the license agreement with Steep Hill, impaired 100% of the value of the Steep Hill Labs licenses due to the purported unsubstantiated termination of the license agreements in June 2016 between Steep Hill Labs and MA & Associates, LLC and Harris Lee, LLC respectively.
 
In 2015, MA and Associates, LLC entered into various capital lease agreements to finance fixed asset purchases for approximately $615,000. Total monthly payments over the 36 month terms are approximately $17,000.
 
The Company's subsidiary MA and Associates, LLC rents space in Nevada with a 60 month term ending in May of 2019, with monthly rent expense of $2,242.

The Company rents office space in New Jersey with a term ending on May of 2018 and monthly payments of approximately $700.

As of September 30, 2017 the Company was still obligated to pay the remaining portion under the original 2014 40% investment agreement with MA and Associates, LLC, consisting of $678,000 of cash and 50,000 shares of Series C Preferred Stock (valued at $35,000 as of September 30, 2017), totaling $713,581 and included in contingent consideration liability on the accompanying consolidated balance sheet and will be issued in the future after the testing laboratory is operational.

On or about April 21, 2017, Eri Eveland filed a Complaint in District Court of Denver County Colorado against Harris Lee Colorado, LLC, Harris Lee Holdings, LLC and Pazoo Inc.  Ms. Eveland is a former employee of Harris Lee Colorado, LLC and is claiming less than $15,000 in unpaid salary/wages.  Inasmuch as Ms. Eveland was not an employee of Harris Lee Holdings, LLC nor Pazoo, Inc., her claims against the Company are derivative in nature and based on theories of corporate alter ego.  The Company disputes any liability.  As of the date of this report, neither Harris Lee Holdings, LLC nor Pazoo, Inc. have been served with the Complaint.  The Company feels it has many valid defenses to this action and, once served, will seek to have the Complaint summarily dismissed as to the Company.
 
On or about June 21, 2017 the Company received a Subpoena from the United States District Court for the District of New Jersey seeking documents in aid of certain legal actions (civil and criminal) surrounding the sale of the Company's stock in 2012-2013.  The Company has complied with the Subpoena and has provided the requested documents. Neither the Company nor any of its officers and/or directors have been named as defendants in either the civil or criminal matter.
 
Note 11—SUBSEQUENT EVENTS
 
The company issued an aggregate of 746,055,920 common shares for conversion of debt and for the settlement of other liabilities valued at a total of $173,817.

The company issued a convertible note of $4,000 which carries a maturity date of August 2018, an interest rate of 12% and a conversion discount of 35% of the lowest price of the previous 15 trading days.

The company issued a promissory note totaling $28,000 which carries an 8% interest rate and a maturity date of November 2018.

In the fourth quarter 2017 the Company sold a 70% Membership Interest in its wholly owned subsidiary (MA & Associates, LLC) in consideration of retirement of approximately $1,000,000 in the Company's debt andapproximately $500,000 in cash (of which $117,894 was funded as of September 30, 2017). The buyer also has an option to buy an additional 10%. The Company must open the lab by February 15, 2018 or it will be considered an event of default. The Company will account for their remaining 30% interest as an equity level investment going forward.

Subsequent to quarter end, with the sale of the 70% interest in MA, the Company will account for this investment under the equity method.  As of September 30, 2017 and December 31, 2016, total assets of MA were approximately $490,930 and $617,321, respectively and total liabilities were $678,770 and $521,743, respectively. Net loss for the three and nine months ended September 30, 2017 was approximately $162,582 and $389,194, respectively. Net loss for the three and nine months ended September 30, 2016 was approximately $91,198 and $1,544,083, respectively.
 
 
Item 2     Management's Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Any statements in this Quarterly Report that are not statements of historical facts are forward-looking statements, which involve risks and uncertainties. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," and similar expressions are intended to identify forward-looking statements. Our actual results may differ materially from those indicated in the forward-looking statements as a result of the factors set forth elsewhere in this Quarterly Report on Form 10-Q. You should read the following discussion and analysis together with our unaudited financial statements for the periods specified and the related notes included herein. Further reference should be made to our Registration Statement on Form 10-K filed with the Securities and Exchange Commission.
 
This Quarterly Report on Form 10-Q contains terminology referring to Pazoo, Inc., such as "us," "our," and "the Company."
 
Management intends the following discussion to assist in the understanding of our financial position and our results of operations for the nine months ended September 30, 2016 and September 30, 2017.

Overview
 
We were incorporated as a C-Corporation in the State of Nevada as IUCSS, Inc. on November 16, 2010 and we established a fiscal year end of December 31.  On May 9, 2011, we changed our name to Pazoo, Inc. to take advantage of unique branding and website opportunities. We are a start-up health and wellness social community that has developed its website (www.pazoo.com) to provide information, services, and online products for improvement of everyday living.  Our mission is to be 1) a leading social community offering best-in-class health and wellness products for both people and pets; 2) an important resource for consumers and professionals with diverse information about health and wellness and 3) specifically as it relates to medical marijuana and the testing of medical marijuana to ensure quality and safety for the consumer.

Our principal executive offices are located at 34 DeForest Ave, Unit 9, East Hanover NJ 07936. Our telephone number is (855) PAZOO-US. Our internet address is www.pazoo.com.

We are a health and wellness company. Presently, our only sources of revenue are pazoo.com and management fees derived from Harris Lee Holdings, LLC. Pazoo.com is an online, content driven, advertising supported health and wellness web site for people and their pets. This site has e-commerce functionality which allows pazoo.com to be an online retailer of nutritional foods/supplements, wellness goods, and fitness apparel. The Company has also moved into the cannabis industry where it seeks to provide, through its wholly owned subsidiaries (MA & Associates, LLC and previously Harris Lee Holdings, LLC), quality control services to the medical and recreational cannabis industry.  The Company's primary mission is to protect the public health by providing infrastructure and analytical services to legally authorized distributors and producers of cannabis and to regulators tracking their operations.  The Company will provide the medical cannabis industry guidelines on how the regulation and inspection by public health authorities is to be implemented.  It is anticipated that this segment of the company will be its primary revenue source in the future. The cannabis industry is heavily regulated on the Federal, State and Local levels and the Company is subject to changing regulation and enforcement. As of December 31, 2016, the cannabis testing laboratory in Denver, Colorado is closed and the Company does not have any plans to re-open the facility in the near future.

Lines of Business
 
We currently have two lines of business relating to and revolving around the health and wellness arena; at this time no significant revenue has been derived from any of these sources.
 
Pharmaceutical Testing Facilities.   We entered this arena through our acquisition of a 100% equity stake in MA & Associates, LLC in order to set up two testing locations.   MA & Associates, LLC was launched in September of 2013 to provide quality control services to the medical cannabis industry. MA & Associates, LLC's primary mission is to protect the public health by providing infrastructure and analytical services to legally authorized distributors and producers of cannabis and to regulators tracking their operations.  In the fourth quarter 2017 the Company sold a 70% Membership Interest in its wholly owned subsidiary (MA & Associates, LLC) in consideration for retirement of approximately $1,000,000 in the Company's debt andapproximately $500,000 in cash (of which $117,894 was funded as of September 30, 2017). The buyer also has an option to buy an additional 10%. The Company must open the lab by February 15, 2018 or it will be considered an event of default. The Company will account for their remaining 30% interest as an equity level investment going forward.
 

 
MA & Associates, LLC will provide the medical cannabis industry guidelines on how the regulation and inspection by public health authorities is to be implemented.  MA & Associates, LLC's primary customer base includes all of the licensed cannabis cultivators, in the State of Nevada, who are required by law to have their products tested before they can be transferred to the dispensaries.  MA & Associates received its operational license from the State of Nevada on January 4, 2017. The Company expects MA & Associates to be fully operational and revenue generating in the upcoming months. Furthermore, we have acquired all of the Membership interest in Harris Lee Holdings, LLC. Harris Lee was set up to take the MA model and testing operations to additional states above and beyond Nevada either in direct testing laboratories or through licensing the testing protocol. As such, we are in a unique position to provide the mandated health and safety testing in this burgeoning industry.  Lastly, Harris Lee Holdings, LLC, due to Colorado residency requirements, entered into an advisory agreement with Harris Lee Colorado, LLC, Harris Lee Holdings, LLC has sub-licensed the testing protocols to Harris Lee Colorado, LLC in exchange for a management fee for each test conducted.  The Colorado MED approved the transfer of management of an existing laboratory, operating as Steep Hill Colorado, to Harris Lee Colorado, LLC (a related party) and Harris Lee Holdings, LLC has derived management fees from Harris Lee Colorado, LLC in the year ending December 31, 2016.  All 2016 revenue was derived from these related-party management fees for the year ended December 31, 2016. However, because of the failure to transfer the MED license to Harris Lee Colorado, LLC, the Denver laboratory was closed by the end 2016. Currently, operations have not come back online and the Company is concentrating its focus on MA & Associates, LLC in Nevada. In the fourth quarter 2017 the Company sold a 70% Membership Interest in its wholly owned subsidiary (MA & Associates, LLC) in consideration for retirement of approximately $1,000,000 in the Company's debt and approximately $500,000 in cash (of which $117,894 was funded as of September 30, 2017). The buyer also has an option to buy an additional 10%. The Company must open the lab by February 15, 2018 or it will be considered an event of default. The Company will account for their remaining 30% interest as an equity level investment going forward.
 
Advertising Revenue from our Website, www.pazoo.com.  Through advertising providers and agencies, pazoo.com is paid for every ad impression that appears on a page for which a visitor goes to. As we build our visitor base, ad revenue is anticipated to increase. However, just having the traffic does not effectively increase advertising revenue. To get the full value of each visitor, the time on site must be long enough so that a visitor is interested in going to multiple pages for which there are ads on each page. The only way this will transpire is if the visitor's experience is gratifying. This is why pazoo.com is so focused on quality content that's interesting and informative. A bad visitor experience will result in a low time on site and fewer page views. Internet tracking tools have much improved over the past decade and will continue to improve in the coming years, especially when it comes to advertising and overall website analytics. Pazoo continues to constantly improve is this area at all times.

Pazoo.com has a unique and compelling online marketing platform. Pazoo.com offers the following important marketing advantages to its target audiences:
 
1.
A comprehensive solution as a content source – information on a full spectrum of disciplines within the health and wellness marketplace;
2.
Health and wellness experts that have expertise in these varied disciplines and write about their areas expertise; and
3.
Content that is both for the health and wellness of people as well as their pets (over 50% of American homes have pets).
4.
Content in the Health and Wellness sector of cannabis.  To empower users to read and learn about the benefits and the need for the testing of the cannabis plant.

Critical Accounting Policy and Estimates
 
Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.  The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period.  On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
 
Results of Operations
Comparison of the three months ended September 30, 2017 to the three months ended September 30, 2016

Revenues. We had revenues of $11,919 and $0 in the three months ended September 30, 2016 and September 30, 2017, respectively.  The decrease is primarily due to the closing of the Harris Lee Colorado Lab in Colorado in September of 2016.

Operating Expenses. Operating expenses consisted primarily of selling, general and administrative expenses and professional fees. Total operating expenses increased to $269,732 for the three month period ended September 30, 2017 from $219,422 for the three month period ended September 30, 2016. 
 

Selling, General and Administrative expenses increased to $188,173 from $164,144, for the three months ended September 30, 2017 compared to the three months ended September 30, 2016 which was mainly comprised of increases in administrative fees, stock compensation, and marketing & advertising.
 
Professional fees increased to $81,559 from $55,278 for the three months ended September 30, 2017 compared to the three months ended September 30, 2016. The increase in professional fees was attributed to an increase in consultants as well as an increase in legal fees.
 
Other income (expense): Our other income (expenses) decreased to ($2,621,116) from $115,228 for the three months September 30, 2017 compared to the three months ended September 30, 2016. Increase in gain (loss) on the derivative liabilities is mostly due to stock fluctuations and changes in the market. The decrease in gain (loss) on debt extinguishment is also attributable to less debt being converted in the three months ended September 30, 2017 as well as the change in interest expense during the same period.

Net Income (Loss). Our net loss increased to a net loss of $2,890,848 for the three months ended September 30, 2017 compared to a net loss of $92,275 for the same period in 2016. The increase is primarily attributable to the loss on change in value of derivative offset by the decrease in interest expense.

Comparison of the nine months ended September 30, 2017 to the nine months ended September 30, 2016 

Net Sales.  We had net sales of $51 and $30,515 in the nine months ended September 30, 2017 and September 30, 2016, respectively. This was due to a decrease in online advertising and a shift of focus to the testing laboratory in Las Vegas Nevada as well as the closing of the Harris Lee Colorado Lab in Colorado back in September of 2016.
 
Operating Expenses.  Operating expenses consisted primarily of selling, general and administrative expenses, professional fees and website set up.  Total operating expenses decreased to $1,482,063 for the nine month period ended September 30, 2017 from $4,159,683 for the nine month period ended September 30, 2016. The decrease in loss of impairment on the license was a major factor in the decrease from the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016
 
Selling, General and Administrative expenses decreased to $1,053,777 from $2,292,314, for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016 which was mainly comprised of administrative fees, stock compensation, and marketing & advertising.  The SG&A decrease was due primarily to decreased administrative costs as compared to 2016 as the focus of the company has shifted to the testing laboratory in Nevada. The decrease in stock compensation is mostly due to the one million settlement of shares and warrants in June 30, 2016.
 
Professional fees increased to $428,286 from $327,162 for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. The increase in professional fees was attributed to an increase in investor relations and financial consultants.
 
Other income (expense): Our other income (expenses) decreased to $(2,558,489) from ($4,287,872) for the nine months ended September, 2017 compared to the nine months ended September 30, 2016. The decrease in interest expense is mostly due to the company taking less convertible debt. Increase in gain (loss) on the derivative liabilities is mostly due stock fluctuation and changes in the market.
 
Net Income (Loss).  Our net loss decreased to $4,040,501 for the nine months ended September 30, 2017 compared to $8,417,040 for the same period in 2016. The decrease is primarily attributable to gain (loss) on debt extinguishment from the various debt conversions in each period and decrease in operating loss. The decrease in interest expense was mostly due to amortization of debt discounts and derivative liability from initial loss on debt discount. Because less notes were acquired in the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016, both interest expense and derivative liability decreased, as well as some of the other debt discounts fully amortized.

Liquidity and Capital Resources
 
As of September 30, 2017 and December 31, 2016, the Company had cash and cash equivalents of $39,047 and $88,909.
  
The Company has no agreements, arrangements or understandings with any officer, director or shareholder as to any future financing, either equity or debt. In view of general economic conditions, there can be no assurance that any additional financing will be available to us, that any affiliate will provide additional investments in the Company or that adequate funds for our operations will otherwise be available when needed or on terms acceptable to us.
   
We had negative working capital of $11,197,052 as of September 30, 2017 as well as sixteen notes with past due principal balances totaling $1,504,152 and accrued default interest and associated penalties related to these instruments.
  
We used $995,173 in operating activities for the nine months ended September 30, 2017 compared to $776,356 for the nine months ended September 30, 2016, which included a net loss of $4,040,501 and $8,417,040 respectively.
 
 
We had $945,311provided by financing activities in the nine month period ended September 30, 2017 compared to $762,713 for the nine months ended September 30, 2016, due primarily to proceeds from loans payable and convertible debt.
 
The consolidated financial statements included in this report have been prepared in conformity with generally accepted accounting principles that contemplate our continuance as a going concern. The Company has had minimal revenues and has generated losses from operation. As set forth in Note 2 of these financial statements, the continuation of the Company as a going concern is dependent upon the Company obtaining adequate capital to fund operating losses until it becomes profitable, if ever. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company's continuation as a going concern is dependent upon our ability to generate sufficient cash flow and raise additional capital to meet our obligations on a timely basis and ultimately attain profitability.  If the Company is unable to generate sufficient cash flow or raise additional capital, it could be forced to cease operations.  The Company's continuation as a going concern is dependent upon our ability to generate sufficient cash flow and raise additional capital to meet our obligations on a timely basis and ultimately attain profitability. The Company does not have sufficient capital for the next 12 months from the issuance of these financial statements.
 
Off-Balance Sheet Arrangements.  We have no off-balance sheet arrangements.
 
Item 3     Quantitative and Qualitative Disclosures About Market Risk
 
As a "smaller reporting company", as defined by Item 10(f) of Regulation S-K, we are not required to provide the information required by Item 3.
 
Item 4     Controls and Procedures

Evaluation of disclosure controls and procedures.
 
We carried out an evaluation, under the supervision of and with our executive officers, Steve Basloe in his role as Chief Executive Officer and Ben Hoehn in his role as Chief Operating Officer and Acting Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934).  Based upon that evaluation, the officers concluded that because of the limited size and resources of our organization our disclosure controls and procedures are not effective as of September 30, 2017.
 
We have not made any changes in our internal control over financial reporting during the nine months ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
 


PART II – OTHER INFORMATION 

Item 1     Legal Proceedings 

In April 2013, the Company filed a complaint against Edataworx, Inc. for return of monies and stock under an agreement dated August 2012. On November 4, 2013, the Company filed an amended complaint now seeking total damages of $105,000 and a return, for cancellation, of the 20,000 shares of company's common stock issued to Edataworx Inc.  On November 21, 2013 Edataworx, Inc. filed an Answer to the Amended Complaint denying the allegations and asserted a Counter-Claim against the Company in the amount of $25,000. Edataworx, Inc. also filed a Third-Party Complaint against Integrated Capital Partners, Inc. (an investor of the Company) for the same $25,000. On February 27, 2015, the parties agreed to settle all claims whereby Edataworx, Inc. will pay to the Company a total of $35,000 in three installments.  Additionally, Edataworx, Inc. will be allowed to retain a minimum of 15,000 shares of the Company's common stock previously issued with the possibility to retain all 20,000 shares if Edataworx Inc. elects to sell the 15,000 shares agreed upon, and the aggregate sales price is less than $2.00 per share. Edataworx, Inc. failed to make any required payments.  On February 25, 2016 new action to enforce the Settlement Agreement, including a claim for attorney's fees as provided for in the Settlement Agreement, was filed.  Edataworx failed to respond to the Complaint in the action to enforce the Settlement Agreement.  On September 16, 2016 a Judgment was entered in favor of the Company in the Amount of $35,012.  The Company is currently seeking to enforce the Judgment.

On or about April 21, 2017, Eri Eveland filed a Complaint in District Court of Denver County Colorado against Harris Lee Colorado, LLC, Harris Lee Holdings, LLC and Pazoo Inc.  Ms. Eveland is a former employee of Harris Lee Colorado, LLC and is claiming less than $15,000 in unpaid salary/wages.  Inasmuch as Ms. Eveland was not an employee of Harris Lee Holdings, LLC nor Pazoo, Inc., her claims against the Company are derivative in nature and based on theories of corporate alter ego.  The Company disputes any liability.  As of the date of this report, neither Harris Lee Holdings, LLC nor Pazoo, Inc. have been served with the Complaint.  The Company feels it has many valid defenses to this action and, once served, will seek to have the Complaint summarily dismissed as to the Company.

On or about June 21, 2017 the Company received a Subpoena from the United States District Court for the District of New Jersey seeking documents in aid of certain legal actions (civil and criminal) surrounding the sale of the Company's stock in 2012-2013.  The Company has complied with the Subpoena and has provided the requested documents. Neither the Company nor any of its officers and/or directors have been named as defendants in either the civil or criminal matter.

Item 1A   Risk Factors
 
As a "smaller reporting company" as defined by Item 10(f) of Regulation S-K, we are not required to provide information required by this item. 
 
Item 2     Unregistered Sales of Equity Securities and Use of Proceeds 

None.
 
Item 3     Defaults Upon Senior Securities 
 
None. 
 
Item 4     (Reserved) 
 
 
Item 5     Other Information 
 
None. 
 
Item 6     Exhibits
 
Exhibit
Number
 
Description
 
 
 
 
 
 
 
 
 
 
SIGNATURE
 
In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
February 7, 2018
PAZOO, INC.
 
 
 
 
 
/s/ Steve Basloe
 
 
Steve Basloe
 
 
Chief Executive Officer
 
 
 
 
 
 
 
February 7, 2018
PAZOO, INC.
 
 
 
 
 
/s/ Ben Hoehn
 
 
Ben Hoehn
 
 
Chief Operating Officer, Acting Chief Financial Officer (Principal Financial and Accounting Officer)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20